Last reviewed · How we verify

Exposure to Plutonium Radiation — Treatment Landscape & Competitive Intelligence

Exposure to Plutonium Radiation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Exposure to Plutonium Radiation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pentetate Calcium Trisodium PENTETATE CALCIUM TRISODIUM Hameln pentetate calcium trisodium 2004-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Hameln · 1 drug in Exposure to Plutonium Radiation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Exposure to Plutonium Radiation:

Cite this brief

Drug Landscape (2026). Exposure to Plutonium Radiation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/exposure-to-plutonium-radiation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing